Evidence map›Paper›PMID 32050434›Full record

ArticleAntibiotics (Basel, Switzerland)2020

Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant

Antonio Vena, Daniele Roberto Giacobbe, Nadia Castaldo, Annamaria Cattelan, Cristina Mussini, Roberto Luzzati, Francesco Giuseppe De Rosa, Filippo Del Puente, Claudio Maria Mastroianni, Antonio Cascio and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Antonio VenaDepartment of Health Sciences, Infectious Disease Clinic, University of Genoa, Genoa 16132, Italy.
Daniele Roberto GiacobbeDepartment of Health Sciences, Infectious Disease Clinic, University of Genoa, Genoa 16132, Italy.
Nadia CastaldoInfectious Diseases Clinic, Department of Medicine University of Udine and Azienda Sanitaria Universitaria Integrata, Udine 33100, Italy.
Annamaria CattelanInfectious Diseases Unit, Department of Internal Medicine, Azienda Ospedaliera-Universitaria di Padova, Padua 35128, Italy.
Cristina MussiniInfectious Diseases Clinics, University of Modena and Reggio Emilia, Modena 41121, Italy.
Roberto LuzzatiInfectious Diseases Unit, University Hospital of Trieste, Trieste 34127, Italy.
Francesco Giuseppe De RosaDepartment of Medical Sciences, Infectious Diseases, University of Turin, Turin 10124, Italy.
Filippo Del PuenteDepartment of Health Sciences, Infectious Disease Clinic, University of Genoa, Genoa 16132, Italy.
Claudio Maria MastroianniDepartment of Anesthesiology, Critical Care Medicine and Pain Therapy, Sapienza University of Rome, Rome 00185, Italy.
Antonio CascioDepartment of Health Promotion Sciences, Mother and Infant Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo 90133, Italy.
Sergio CarbonaraClinic of Infectious Diseases, University Hospital of Bari Consorziale Policlinico, Bari 70121, Italy.
Alessandro CaponeClinical Department, National Institute for Infectious Diseases "L. Spallanzani", Rome 00149, Italy.
Silvia BoniDivisione di Malattie Infettive, Ospedale Sant'Andrea, La Spezia 19121, Italy.
Chiara SepulcriDepartment of Health Sciences, Infectious Disease Clinic, University of Genoa, Genoa 16132, Italy.
Marianna MeschiariInfectious Diseases Clinics, University of Modena and Reggio Emilia, Modena 41121, Italy.
Francesca RaumerInfectious Diseases Unit, Department of Internal Medicine, Azienda Ospedaliera-Universitaria di Padova, Padua 35128, Italy.
Alessandra OlivaDepartment of Anesthesiology, Critical Care Medicine and Pain Therapy, Sapienza University of Rome, Rome 00185, Italy.
Silvia CorcioneDepartment of Medical Sciences, Infectious Diseases, University of Turin, Turin 10124, Italy.
Matteo BassettiDepartment of Health Sciences, Infectious Disease Clinic, University of Genoa, Genoa 16132, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExperience in real clinical practice with ceftazidime-avibactam for the treatment of serious infections due to gram-negative bacteria (GNB) other than carbapenem-resistant

methodsWe carried out a retrospective multicenter study of patients hospitalized in 13 Italian hospitals who received ≤72 h of ceftazidime-avibactam for GNB other than CRE to assess the rates of clinical success, resistance development, and occurrence of adverse events.

resultsCeftazidime-avibactam was used to treat 41 patients with GNB infections other than CRE. Median age was 62 years and 68% of them were male. The main causative agents were

conclusionsCeftazidime-avibactam may be a valuable therapeutic option for serious infections due to GNB other than CRE.

Indexed as

carbapenem-sparing regimenceftazidime-avibactamESBL-producing Enterobacteralesnosocomial pneumoniaPseudomonas aeruginosa

Identifiers

PMID32050434
PMCPMC7168189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.